A phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue 4, 2004, Pages 250-254

  Steele, Julie ^a   Matos, Luis A ^a   Lopez, Eustorgio A ^a   Perez Pinzon, Miguel A ^a   Prado, Ricardo ^a   Busto, Raul ^a   Arheart, Kristopher L E ^a   Bradley, Walter G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ALS; Hyperbaric oxygen; Muscle strength; Therapeutic trial

Indexed keywords

OXYGEN; PLACEBO;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATMOSPHERIC PRESSURE; CASE REPORT; CLINICAL TRIAL; DETERIORATION; DISEASE EXACERBATION; DRUG SAFETY; FATIGUE; FEMALE; HAND GRIP; HUMAN; HYPERBARIC OXYGEN; LEARNING; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; NEUROLOGIC EXAMINATION; NEUROMUSCULAR FUNCTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; HYPERBARIC OXYGENATION; LINEAR MODELS; MALE; MIDDLE AGED;

EID: 12344328378     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820410021285     Document Type: Article

References (47)

1. Data Warehouse Centers for Disease Control. http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/gmwki10.htm
2. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 33: 585-591.
3. Groeneveld GJ, Van Kan HJ, Kalmijn S et al. Riluzole serum concentrations in patients with ALS: associations with side-effects and symptoms. Neurology 2003; 61: 1141-1143.
4. Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
5. Bertamini M, Marzani B, Guarneri R et al. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur J Neurosci 2002; 16: 2291-2296.
6. Gillingwater TH, Ribchester RR. The relationship of neuromuscular synapse elimination to synaptic degeneration and pathology: insights from Wld(S) and other mutant mice. J Neurocytol 2003; 32: 863-881.
7. Maddatu TP, Garvey SM, Shroeder DG et al. Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum Mol Genet 2004; 13: 1105-1115.
8. Papapetropoulos TA, Bradley WG. Spinal motor neurons in murine muscular dystrophy and spinal muscular atrophy. J Neurology Neurosurgery Psvchiatry 1972; 35: 60-65.
9. Dave KR, Prado R, Busto R et al. Hyperbaric oxygen therapy protects against mitochondrial dysfunction and delays onset of motor neuron disease in wobbler mice. Neuroscience 2003; 120: 113-120.
10. Jaarsma D, Haasdijk ED, Grashorn JA et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motor neuron death and accelerates motor neuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol Dis 2000; 7: 623-643.
11. Vielhaber S, Kunz D, Winkler K et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 2000; 123: 1339-1348.
12. Swerdlow RH, Parks JK, Pattee G et al. Role of mitochondria in amyotrophic lateral sclerosis. ALS 2000; 1: 185-190.
13. Xu GP, Dave KR, Moraes CT et al. Dysfunctional mitochondrial respiration in the wobbler mouse brain. Neurosci Lett 2001; 300: 141-144.
14. Finsterer J. Mitochondriopathy as a differential diagnosis of amyotrophic lateral sclerosis. ALS 2002; 3: 219-224.
15. Menzies FM, Cookson MR, Taylor RW et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002; 125: 1522-1533.
16. Mattiazzi M, D'Aurelio M, Gajewski CD et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem 2002; 277: 29626-29633.
17. Chung MJ, Suh YL. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct Pathol 2002; 26: 3-7.
18. Wiedemann FR, Manfredi G, Mawrin C et al. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002; 80: 616-625.
19. Cookson MR, Shaw PJ. Oxidative stress and motor neuron disease. Brain Pathol 1999; 9: 165-186.
20. Borthwick GM, Johnson MA, Ince PG et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999; 46: 787-790.
21. Lee M, Hyun D, Jenner P et al. Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J Neurochem 2001; 76: 957-965.
22. Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosc 2002; 5: 291-309.
23. Brooks BR, Miller RG, Munsat TL, for the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS 2000; 1: 293-299.
24. Munsat TL, Andres PL, Finison L et al. The natural history of motor neuron loss in ALS. Neurology 1988; 38: 452-458.
25. Cederbaum JM, Stampler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999; 169: 13-21.
26. Hughes J. Pathology of amyotrophic lateral sclerosis. Adv Neurol 1982; 36: 61-73.
27. Stampler N, Charatan M, Cederbaum JM, the ALS CNTF Treatment Study (ACTS) Group. Prognostic indicators of survival in ALS. Neurology 1998; 50: 66-72.
28. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods, 2nd edn. Thousand Oaks, CA: Sage Publishing Co., 2002.
29. Diggle PJ, Liang K, Zeger SL. Analysis of Longitudinal Data. NY: Oxford University Press, 1994.
30. McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. Boca Raton, FL: Chapman & Hall/CRC, 1989.
31. Andres PL, Finison LJ, Conlon T et al. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988; 38: 405-408.
32. Bruijn LI, Miller TM, Cleveland DW. Unravelling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004; 27: 723-749.
33. Azzouz M, Ralph GS, Storkebaum E et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-417.
34. Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motor neurons against ischemic death. Nat Genet 2003; 34: 383-394.
35. Skene JP, Cleveland DW. Hypoxia and Lou Gehrig. Nat Genet 2001; 28: 107-108.
36. Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 2003; 22: 217-228.
37. Delsite RL, Rasmussen LJ, Rasmussen AK et al. Mitochondrial impairment is accompanied by impaired oxidative DNA repair in the nucleus. Mutagenesis 2003; 18: 497-503.
38. Migliore L, Molinu S, Naccarati A et al. Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis 2004; 19: 43-49.
39. Goto S, Nakamura H, Morooka H et al. Role of reactive oxygen in phospholipase A2 activation by ischemia/reperfusion of the rat kidney. J Anesth 1999; 13: 90-93.
40. Liu Y, Bao J, Lai H et al. Structural changes of neurons in hippocampus from infantile rats exposed to hyperbaric oxygen. Chin J Traumatol 2000; 3: 206-209.
41. Hoagland RJ, Mendoza M, Armon C et al. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with ALS. Muscle & Nerve 1997; 20: 691-695.
42. The ALS CNTF Treatment Study Group. A double-blind controlled clinical trial of recombinant human ciliary neurotrophic factor (rHCNTF) in ALS. Neurology 1996; 46: 1244-1249.
43. Bradley WGthe BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS (Phase III). Neurology 1999; 52: 1427-1433.
44. Rosenfeld J, King RM, Smith JE. Oxandrolone in ALS: Preliminary analysis. ALS 2000; 4 (Suppl): 21-26.
45. Miller RG, Moore DH, Gelinas DF et al. Phase III randomized trial of gabapentin in patients with ALS. Neurology 2001; 56: 843-848.
46. Groeneveld GJ, Veldink JH, van der Tweel I et al. A randomized sequential trial of creatine in ALS. Ann Neurol 2003; 53: 437-445.
47. Cudkowicz ME, Shefner JM, Schoenfeld DA et al. A randomized, placebo-controlled trial of topiramate in ALS. Neurology 2003; 61: 456-464.